Food Allergy Awareness Week 2024: How can new treatments target an unmet need?
Pharmaceutical Technology
MAY 16, 2024
IgGenix is planning to initiate a clinical trial later this year investigating its peanut allergy monoclonal antibody IGXN001.
Maternal Antibodies: How Allergies Can be Passed from Mothers to Children
XTalks
NOVEMBER 4, 2020
It has long been known that mothers greatly influence the development of the growing fetus by not only providing nutrients through the placenta, but also a growing list of biological elements including beneficial antibodies, gut bacteria and now, allergies. Related: Red Meat Allergy Test Gets FDA Clearance.
Allergies 
98
98 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Re-examining antibodies' role in childhood allergies
Medical Xpress
DECEMBER 2, 2022
The presence of food-specific IgA antibodies in the gut does not prevent peanut or egg allergies from developing in children, according to a Northwestern Medicine study published in Science Translational Medicine.
Allergies 81
81 
Omlyclo Becomes First Biosimilar to Rival Xolair
XTalks
MARCH 10, 2025
Originally approved by the FDA over two decades ago for the treatment of moderate to severe persistent asthma, Xolair recently also gained approval for managing food allergies. Omalizumab is an anti-IgE antibody that works by blocking the effects of IgE, a key driver in many allergic reactions. billion by 2030.
Allergies 66
66 
Asthma Drug Xolair Wins FDA Approval as First Treatment for Multiple Food Allergies
XTalks
FEBRUARY 26, 2024
The class of IgE-mediated food allergies includes 160 foods, with peanuts, milk, eggs, wheat, soy and tree nuts being the most common ones. According to the Centers for Disease Control and Prevention (CDC), almost six percent of people in the US in 2021 had a food allergy. However, the treatment is restricted to peanut allergy.
Allergies 100
100 
IgGenix Launches with $10 Million to Develop Therapeutics for Severe Allergies
BioSpace
AUGUST 4, 2020
emerged from stealth mode with $10 million in Series A financing and a goal to advance the company’s novel antibody therapeutics platform for the treatment of food and non-food allergies, as well as other severe allergic conditions. Startup IgGenix, Inc.
Allergies 82
82 
NIAID drops Lilly antibody from ACTIV-3 COVID-19 trial
pharmaphorum
OCTOBER 27, 2020
Eli Lilly says no more patients will be treated with its COVID-19 therapy bamlanivimab in a trial run by the US National Institute of Allergy and Infectious Diseases (NIAID), as results to date suggest it is unlikely to be effective. The post NIAID drops Lilly antibody from ACTIV-3 COVID-19 trial appeared first on.
Antibody 105
105 
US buys Lilly COVID antibody, as effectiveness questions remain
pharmaphorum
OCTOBER 28, 2020
Our goal is to ensure that Lilly antibody treatments are available to patients who need them, no matter where they live. “As As long as supply of neutralising antibodies is constrained, we believe the only way to ensure equitable access is for Lilly to contract directly with governments and pan-national philanthropic organisations. “As
Antibody 104
104 
Antibody treatment improves chronic food allergy symptoms in young adults, study finds
Medical Xpress
DECEMBER 22, 2022
A weekly dose of dupilumab, a monoclonal antibody, led to a reduction of symptoms and tissue improvement in young adults and adolescents with eosinophilic esophagitis (EoE), according to a new study published in the New England Journal of Medicine.
Antibody 75
75 
Large NIH clinical trial will test polyclonal antibody therapeutic for COVID-19
Scienmag
APRIL 21, 2021
Credit: NIAID A Phase 2/3 trial to evaluate a new fully-human polyclonal antibody therapeutic targeted to SARS-CoV-2, called SAB-185, has begun enrolling non-hospitalized people with mild or moderate cases of COVID-19.
Antibody 81
81 
UTMB study shows common antibody therapy has anti-SARS-CoV-2 Antibodies
Scienmag
APRIL 25, 2022
GALVESTON, Texas – Researchers at the University of Texas Medical Branch recently confirmed the presence of neutralizing antibodies to SARS–COV-2 in a common subcutaneous antibody therapy (Hizentra) used to treat immunocompromised or immunodeficient patients, citing its protective benefits to the immunocompromised patient community.
Antibody 61
61 
New serological assay provides rapid, accurate testing for SARS-CoV-2 antibodies
Scienmag
DECEMBER 10, 2020
Using optical biosensor technology, the test provides quantitative measurements of antibodies in blood plasma in less than 20 minutes Credit: Carolyn Lagattuta Researchers at UC Santa Cruz have developed a novel serological assay for the detection of antibodies to SARS-CoV-2, the coronavirus that causes COVID-19.
Antibody 98
98 
COVID-19 antibodies persist at least nine months after infection
Scienmag
JULY 19, 2021
Credit: Andrea Crisanti Testing of an entire Italian town shows antibody levels remain high nine months after SARS-CoV-2 infection, whether symptomatic or asymptomatic.
Antibody 100
100 
Antibody cocktails at low doses could be more effective at treating COVID-19
Scienmag
NOVEMBER 19, 2020
Credit: University of North Carolina/Megan May Pairs of antibodies may be more effective than single antibodies at preventing and treating COVID-19, according to a new study by researchers at the University of North Carolina at Chapel Hill and The Rockefeller University in New York.
Antibody 95
95 
Patients with recently discovered antibodies have more severe myasthenia gravis
Scienmag
AUGUST 18, 2020
Credit: Phil Jones, Senior Photographer, Augusta University A study of 181 patients at 16 sites across the country who test negative for two antibodies long known to cause muscle-weakening myasthenia gravis, found that about 15% test positive for one of two newly discovered antibodies that also attack the point of communication between nerves and muscle. (..)
Antibody 85
85 
8 Of The Most Common Foods Allergies – Do You Have One?
Delveinsight
DECEMBER 23, 2020
As per the Food Allergy Research & Education, in the US, each year, around 200,000 people require emergency medical care for allergic reactions to food. Food allergy is a specific immune response to certain food items that it considers harmful. The symptoms of food allergy vary from person to person and can also differ over time.
Allergies 52
52 
NIAID Halts Eli Lilly COVID-19 Antibody Trial
The Pharma Data
OCTOBER 27, 2020
The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) has halted a clinical trial evaluating Eli Lilly’s investigational monoclonal antibody, LY-CoV555 (bamlanivimab), in combination with remdesivir for the treatment of COVID-19 patients. Source link.
Antibody 52
52 
Dried blood spot sampling offers inexpensive way to widen access to antibody testing for COVID-19
Scienmag
OCTOBER 6, 2020
Credit: University of Birmingham Using dried blood spot samples (DBS) is an accurate alternative to venous blood in detecting SARS-CoV-2 antibody tests, a new study by immunology experts at the University of Birmingham has found.
Antibody 83
83 
Antibodies help identify women protected from placental malaria
Scienmag
JUNE 29, 2021
Six antibody features help protect pregnant women against placental malaria infections, and could be used to identify women at risk of the disease and related complications Six antibody characteristics could help scientists identify which pregnant women are at risk of placental malaria infections, finds a study published today in eLife.
Antibody 65
65 
Altered ‘coat’ disguises fatal brain virus from neutralizing antibodies
Scienmag
NOVEMBER 20, 2020
— A genetic modification in the ‘coat’ of a brain infection-causing virus may allow it to escape antibodies, according to Penn State College of Medicine researchers. HERSHEY, Pa. They say testing people for this and other viral mutations may help identify patients at risk for developing a fatal brain disease.
Antibody 71
71 Accuracy of commercial antibody kits for SARS-CoV-2 varies widely
Scienmag
SEPTEMBER 25, 2020
There is wide variation in the performance of commercial kits for detecting antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to a study published September 24 in the open-access journal PLOS Pathogens by Jonathan Edgeworth and Blair Merrick of Guy’s and St Thomas’ NHS Foundation Trust, Suzanne Pickering (..)
Antibody 67
67 
Trial of Antibody Drug for COVID-19 Stopped for Lack of Effectiveness
The Pharma Data
OCTOBER 27, 2020
Trial of Antibody Drug for COVID-19 Stopped for Lack of Effectiveness. 27, 2020 — Testing of the Eli Lilly antibody drug for hospitalized COVID-19 patients has been halted because the treatment does not help them recover from their infection. Professional. TUESDAY, Oct. But the U.S.
Antibody 52
52 
Antibody binding-site conserved across COVID-19 virus variants
Scienmag
APRIL 9, 2021
The structural revelation could have implications as a therapeutic target in all SARS-CoV-2 variants Credit: Kelly Lab/Penn State A tiny protein of SARS-CoV-2, the coronavirus that gives rise to COVID-19, may have big implications for future treatments, according to a team of Penn State researchers.
Antibody 93
93 
Antibody responses in COVID-19 patients could guide vaccine design
Scienmag
SEPTEMBER 11, 2020
Credit: NIAID, 2020 A comprehensive analysis of antibody responses in coronavirus disease 2019 (COVID-19) patients could inform the development of an effective vaccine, according to a study published September 10 in the open-access journal PLOS Pathogens by Chao Wu and Rui Huang of Nanjing University Medical School, and colleagues.
Antibody 61
61 
Temperature-stable tuberculosis vaccine safe, prompts immune response in first-in-human trial
Medical Xpress
MARCH 6, 2023
A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system. A non-temperature stable form of the candidate previously had been tested in several clinical trials.
Valneva eyes first place in chikungunya vaccine race
pharmaphorum
DECEMBER 5, 2022
The French biotech says VLA1553 met its objective in the phase 3 study, with 99% of patients exhibiting an antibody response against the virus 12 months after receiving a single dose of the shot, with no evidence of a tailing off in levels in the last six months. It will continue for up to five years.
Vaccine 98
98 
Zydus starts Phase II COVID-19 vaccine trial; Taysha raises $95M; FDA declines DBV’s peanut allergy patch; Combating COVID-19 with decoy target
Delveinsight
AUGUST 6, 2020
Scientists have already isolated many highly potent neutralizing antibodies from patients who recovered from COVID-19. These antibodies defend a cell from infection by squarely preventing the pathogen’s biological activities. FDA turns back peanut allergy patch of DBV Technologies. The agency raised no safety concerns.
Allergies 53
53 
NIAID Halts Eli Lilly COVID-19 Antibody Trial | 2020-10-28
The Pharma Data
OCTOBER 26, 2020
The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) has halted a clinical trial evaluating Eli Lilly’s investigational monoclonal antibody, LY-CoV555 (bamlanivimab), in combination with remdesivir for the treatment of COVID-19 patients.
Antibody 40
40 
UAB researcher develops technology to aid COVID-19 vaccine immunity monitoring
Scienmag
JANUARY 4, 2021
In advance of public vaccination, a quick and accurate COVID-19 antibody test will help determine the presence of neutralizing antibodies, the molecules that aid in protection against the virus. Credit: UAB BIRMINGHAM, Ala.
Vaccine 98
98 
Scientists unmask new neutralizing antibody target on SARS-CoV-2 spike protein
Scienmag
APRIL 22, 2021
SARS-CoV-2 can recruit a haem metabolite to evade antibody immunity Researchers have identified another potential target for neutralizing antibodies on the SARS-CoV-2 Spike protein that is masked by metabolites in the blood.
Antibody 46
46 
FDA Authorizes COVID-19 Vaccine Boosters for Immunocompromised Individuals
XTalks
AUGUST 16, 2021
The majority of patients — 24 patients (80 percent) — had no antibodies against SARS-CoV-2, while six had low levels. After the patients were given a third dose of Pfizer or Moderna, all those with low antibody titers and eight of the antibody negative patients developed high-positive antibody titers two weeks post-vaccination.
Vaccine 104
104 
NIH neuroscientists isolate promising mini antibodies against COVID-19 from a llama
Scienmag
DECEMBER 22, 2020
National Institutes of Health researchers have isolated a set of promising, tiny antibodies, or “nanobodies,” against SARS-CoV-2 that were produced by a llama named Cormac. Preliminary results suggest anti-COVID19 nanobodies may be effective at preventing and diagnosing infections Credit: Courtesy of Brody lab NIH/NINDS.
Antibody 52
52 
Gritstone bio supports mRNA Covid-19 vaccine plans with Phase I publication
Pharmaceutical Technology
JUNE 8, 2023
With respect to immunogenicity, neutralising antibody titers against ancestral Spike and variants of concern were boosted by the samRNA candidate, and contrasting to authorised vaccines, persisted through at least 6 months following the booster dose. According to GlobalData , there are over 800 Covid-19 vaccines in the pipeline, 42.6%
Vaccine 130
130 
Children produce different antibodies in response to SARS-CoV-2
Scienmag
NOVEMBER 5, 2020
5, 2020)–Children and adults produce different types and amounts of antibodies in response to infection with the new coronavirus, SARS-CoV-2, a new study from researchers at Columbia University Vagelos College of Physicians and Surgeons has found. NEW YORK, NY (Nov.
Antibody 40
40 
TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress
The Pharma Data
JULY 11, 2021
3 These data are being presented at the 2021 European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress in Krakow, Poland and Madrid, Spain. TAKHZYRO is a fully human monoclonal antibody that specifically binds and decreases plasma kallikrein activity. All antibody titres were low.
Allergies 52
52 
Rapid method finds potent COVID-19 monoclonal antibody among a trillion possibilities
Scienmag
NOVEMBER 2, 2020
2, 2020 – University of Pittsburgh School of Medicine scientists have discovered the fastest way to identify potent, neutralizing human monoclonal antibodies against SARS-CoV-2, the virus that causes COVID-19. Credit: UPMC PITTSBURGH, Nov.
Antibody 40
40 
Immunotherapy-resistant cancers eliminated in mouse study
Scienmag
AUGUST 11, 2020
Antibody that blocks TREM2 protein frees immune cells to reject cancer Credit: William Vermi/Martina Molgora Immunotherapy has revolutionized cancer treatment by stimulating the patient’s own immune system to attack cancer cells, yielding remarkably quick and complete remission in some cases.
Protein 95
95 
Dupixent falls short in phase 3 chronic spontaneous urticaria trial
pharmaphorum
FEBRUARY 18, 2022
In CUPID STUDY B, IL-4 and IL-13 inhibitor Dupixent (dupilumab) wasn’t able to achieve a significant improvement in symptoms in Xolair-refractory CSU patients, and will be stopped for futility, although the antibody did show “numeric improvements” on itching and hive symptoms, according to its developers.
Trials 105
105 
Pregnant women show robust immune response to COVID vaccines, pass antibodies to newborns
Scienmag
MARCH 25, 2021
The largest study of its kind to date also found benefit for lactating women BOSTON – In the largest study of its kind to date, researchers at Massachusetts General Hospital, Brigham and Women’s Hospital and the Ragon Institute of MGH, MIT and Harvard have found the new mRNA COVID-19 vaccines to be highly effective in […].
Pfizer-BioNTech vaccine recipients have lower antibody levels targeting the Delta variant
Scienmag
JUNE 3, 2021
Levels of antibodies in the blood of vaccinated people that are able to recognise and fight the new SARS-CoV-2 Delta variant first discovered in India (B.1.617.2)
Antibody 41
41 
The Lancet: Seroprevalence study from Wuhan suggests 6.9% of population had COVID-19 antibodies by April 2020 — including 40% with neutralizing antibodies that lasted for at least 9 months — but 82% of cases were asymptomatic
Scienmag
MARCH 18, 2021
New study is the first long-term seroprevalence study from Wuhan, China involving over 9,000 residents who were tested for antibodies after the Wuhan lockdown lifted in April, then again in June and in October-December 2020.
Antibody 40
40 
COVID-19 monoclonal antibody therapy can reduce hospitalizations, healthcare system stress
Scienmag
JUNE 23, 2021
A study by the University of South Florida Health and Tampa General Hospital is among the first to assess effectiveness of monoclonal antibodies in a practical setting when given early to patients at high risk for severe COVID-19 TAMPA, Fla. June 24, 2021) — A newly published study by the University of South Florida Health […].
Antibody 40
40 
Antibodies from patients infected with SARS-CoV in 2003 cross-neutralized SARS-CoV-2 in vitro
Scienmag
OCTOBER 9, 2020
Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals Antibodies in serum samples collected from patients infected with SARS-CoV during the 2003 outbreak effectively neutralized SARS-CoV-2 infection in cultured cells, according to a new study.
In-Vitro 40
40 
Let's personalize your content